drugset / Trial / NCT04727684

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

NCT04727684

Phase 4 Completed 50 enrolled Damascus University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Selection of developmentally competent oocytes enhances IVF efficiency. Usually, oocyte quality is determined based on its nuclear maturation and the presence of specific cytoplasmic and extracytoplasmic morphologic features. Gonadotropin-releasing hormone agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists) are used during controlled ovarian stimulation (COS) protocols in order to prevent premature luteinizing hormone (LH) surge and premature ovulation. However, GnRH receptors are also expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type of GnRH analogues used during COS could affect the oocyte morphology in polycystic ovary syndrome (PCOS) patients. The aim of this prospective, non-randomised, open-label, clinical trial is to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on oocyte morphology in PCOS patients during IVF/ICSI.

Timeline

Start
2020-08-22
Primary completion
2022-02-15
Completion
2022-05-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetrorelix Other / unclassified 0.25 mg
Comparator Triptorelin Other / unclassified 0.05 mg Subcutaneous
Comparator Triptorelin Other / unclassified 0.1 mg Subcutaneous
Background Gonal-f Protein / enzyme biologic
Background human chorionic gonadotropin Protein / enzyme biologic 10000 iu
Background human chorionic gonadotropin Protein / enzyme biologic